DRG C-Peptide, 96 Wells
To add this product to your interest list, sign up or login.
Manufacturer: DRG International Inc.
Model: C-Peptide, 96 Wells
Product Code: EIA-1293
The DRG C-Peptide, 96 Wells is an enzyme immunoassay for the quantitative in vitro diagnostic measurement of CPeptide in serum, plasma and urine. To purchase this product conveniently and affordably, you have come to the right place. We are Block Scientific, one of the more popularly known laboratory equipment dealers in Bellport, New York.
C Peptide Elisa
– Quality Product
The DRG C-Peptide ELISA Kit is a solid phase enzyme-linked immunosorbent assay (ELISA), based on the principle of competitive binding.
- Provided reagents – microtiterwells, sample diluent, Standard (Standard 0-5, antiserum, enzyme complex, enzyme conjugate, stop solution, substrate solution, wash solution
- Storage – When stored at 2 °C to 8 °C unopened reagents will retain reactivity until expiration date.
Summary and Explanation
Insulin is synthesized in the pancreatic beta cells as a 6000 MW component of an 86 amino acid polypeptide called proinsulin (1, 2, 3). Proinsulin is subsequently cleaved enzymatically, releasing insulin into the circulation along with a residual 3000 MW fragment called connection (“C”) peptide, so-named because it connects A and B chains of insulin within the proinsulin molecule (1, 2, 3, 4). Human C-Peptide, a 31 amino acid residue peptide, has a molecular mass of approximately 3000 daltons. C-Peptide has no metabolic function. However, since C-Peptide and insulin are secreted in equimolar amounts, the immunoassay of C-Peptide permits the quantitation of insulin secretion (4, 5, 6). This is the reason for the clinical interest of serum and urinary determinations of C-Peptide. Moreover, C-Peptide measurement has several advantages over immunoassays of insulin. The half-life of C-Peptide in the circulation is between two and five times longer than that of insulin (7). Therefore, CPeptide levels are a more stable indicator of insulin secretion than the more rapidly changing levels of insulin. A very clear practical advantage of C-Peptide measurement arising from its relative metabolic inertness as compared to insulin is that C-Peptide levels in peripheral venous blood are about 5-6 times greater than insulin levels (3). Also, relative to an insulin assay, the C-Peptide assay’s advantage is its ability to distinguish endogenous from injected insulin. Thus, low C-Peptide levels are to be expected when insulin is diminished (as in insulin-dependent diabetes) or suppressed (as a normal response to exogenous insulin), whereas elevated C-Peptide levels may result from the increased β-cell activity observed in insulinomas (3, 6, 9). C-Peptide has also been measured as an additional means for evaluating glucose tolerance and glibenclamide glucose tests (2, 3, 9, 10). C-Peptide levels are in many ways a better measurement of endogenous insulin secretion than peripheral insulin levels. CPeptide may be measured in either blood or urine (9). With improved sensitive C-Peptide immunoassays, it is now possible to measure C-Peptide values at extremely low levels. The clinical indications for C-Peptide measurement include diagnosis of insulinoma and differentation from factitious hypoglycemia, follow-up of pancreatectomy, and evaluation of viability of islet cell transplants (11, 12, 13). Recently, these indications have been dramatically expanded to permit evaluation of insulin dependence in maturity onset diabetes mellitus.